Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential inhaled therapy response study in asthma and COPD phenotypes
ACTRN12610000666022Phase 4Completed
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ipratropium bromide, salbutamol and budesonide in asthma, chronic obstructive pulmonary disease (COPD) and airway diseases, sponsored by Medical Research Institute of New Zealand. Primary endpoints: FEV1 response to ipratropium between phenotype groups and FEV1 response to salbutamol between phenotype groups. Started Nov 2010; status: completed.
02
Drugs
ipratropium bromidesalbutamolbudesonide
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)airway diseases
Beyond the preview
Go deeper on ACTRN12610000666022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000666022.